Korean Circ J.  2013 Jul;43(7):443-452. 10.4070/kcj.2013.43.7.443.

The Decline Effect in Cardiovascular Medicine: Is the Effect of Cardiovascular Medicine and Stent on Cardiovascular Events Decline Over the Years?

• Lee MS
• Flammer AJ
• Lerman A

• KMID: 2145499
• DOI: http://doi.org/10.4070/kcj.2013.43.7.443

Abstract

The term decline effect is referred to a diminution of scientifically discovered effects over time. Reasons for the decline effect are multifaceted and include publication bias, selective reporting, outcomes reporting bias, regression to the mean, scientific paradigm shift, overshadowing and habituation, among others. Such effects can be found in cardiovascular medicines through medications (e.g., aspirin, antithrombotics, proton pump inhibitor, beta-blockers, statins, estrogen/progestin, angiotensin converting enzyme inhibitor etc.), as well as with interventional devices (e.g., angioplasty, percutaneous coronary intervention, stents). The scientific community should understand the various dimensions of the decline effects, and effective steps should be undertaken to prevent or recognize such decline effects in cardiovascular medicines.

Keyword

Cardiovascular drug; Stents; Percataneous coronary intervention

MeSH Terms

Angioplasty
Aspirin
Bias (Epidemiology)
Peptidyl-Dipeptidase A
Percutaneous Coronary Intervention
Proton Pumps
Publication Bias
Stents
Aspirin
Peptidyl-Dipeptidase A
Proton Pumps

Reference

1. Schooler J. Unpublished results hide the decline effect. Nature. 2011; 470:437.

2. Lehrer J. The Truth Wears Off-is there something wrong with the scientific method? New Yorker. 2010. 12. 13.

3. Møller AP, Jennions MD. Testing and adjusting for publication bias. Trends Ecol Evol. 2001; 16:580–586.

4. Dwan K, Altman DG, Arnaiz JA, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One. 2008; 3:e3081.

5. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007; 176:1091–1096.

6. Palmer AR. Quasi-replication and the contract of error: lessons from sex ratios, heritabilities and fluctuating asymmetry. Annu Rev Ecol Syst. 2000; 31:441–480.

7. Crabbe JC, Wahlsten D, Dudek BC. Genetics of mouse behavior: interactions with laboratory environment. Science. 1999; 284:1670–1672.

8. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005; 294:218–228.

9. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991; 325:756–762.

10. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995; 273:199–208.

11. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321–333.

12. Hulley S, Grady D, Bush T, et al. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998; 280:605–613.

13. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993; 328:1450–1456.

14. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993; 328:1444–1449.

15. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996; 347:781–786.

16. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000; 342:154–160.

17. Grines CL, Browne KF, Marco J, et al. The Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1993; 328:673–679.

18. Cucherat M, Bonnefoy E, Tremeau G. Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction. Cochrane Database Syst Rev. 2003; CD001560.

19. Fischman DL, Leon MB, Baim DS, et al. Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994; 331:496–501.

20. Serruys PW, de Jaegere P, Kiemeneij F, et al. Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994; 331:489–495.

21. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med. 2003; 138:777–786.

22. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993; 342:1007–1011.

23. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr. 2003; 57:904–908.

24. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989; 321:129–135.

25. US Preventive Services Task Force. Guide to Clinical Preventive Services. Report of the U.S. Preventive Services Task Force. 2nd ed. Baltimore: Williams & Wilkins;1996.

26. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 150:405–410.

27. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002; 136:157–160.

28. U.S. Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease. accessed on July 17, 2013. Available from: http://www.uspreventiveservicestaskforce.org/uspstf09/aspirincvd/aspcvdrs.htm.

29. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011; 107:1796–1801.

30. CURRENT-OASIS 7 Investigators. Mehta SR, Bassand JP, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010; 363:930–942.

31. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010; 376:1233–1243.

32. Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol. 2011; 8:547–559.

33. Bonaca MP, Steg PG, Feldman LJ, et al. Antithrombotics in acute coronary syndromes. J Am Coll Cardiol. 2009; 54:969–984.

34. Lamotte M, Annemans L, Evers T, Kubin M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics. 2006; 24:155–169.

35. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000; 102:624–629.

36. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008; 52:1502–1517.

37. Faxon DP, Freedman JE. Facts and controversies of aspirin and clopidogrel therapy. Am Heart J. 2009; 157:412–422.

38. Cohen M, Théroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J. 2002; 144:470–477.

39. Ferguson JJ, Antman EM, Bates ER, et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003; 146:628–634.

40. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A. Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003; 107:238–244.

41. Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA. The potential of aptamers as anticoagulants. Trends Cardiovasc Med. 2005; 15:41–45.

42. Douketis JD. Combination warfarin-ASA therapy: which patients should receive it, which patients should not, and why? Thromb Res. 2011; 127:513–517.

43. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007; 147:590–592.

44. Leon MB, Baim DS, Popma JJ, et al. Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998; 339:1665–1671.

45. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 150:396–404.

46. Saini SD, Schoenfeld P, Fendrick AM, Scheiman J. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern Med. 2008; 168:1684–1690. discussion 1691.

47. Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011; 171:218–225.

48. Gurbel PA, Tantry US. Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy. Nat Rev Cardiol. 2011; 8:7–8.

49. Gurbel PA, Tantry US, Kereiakes DJ. Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. Drug Healthc Patient Saf. 2010; 2:233–240.

50. US Department of Health & Human services. FDA. Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). 2009. accessed on July 2, 2012. Available from: http://www.fda.gov/Drugs/Drugsafety/PostmarketDrugsafetyinformationforPatientsandProviders/DrugsafetyinformationforHeathcareProfessionals/ucm190787.htm.

51. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton-pump inhibitors. 2009. accessed on July 17, 2013. Available from: www.ema.europa.eu/humandocs/PDFs/ePAR/Plavix/32895609en.pdf.

52. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010; 122:2619–2633.

53. Spoladore R, Fragasso G, Montanaro C, et al. [Present trends and controversies in the use of beta-blockers in cardiovascular diseases]. Recenti Prog Med. 2010; 101:429–441.

54. Corteville B, Gillebert TC. Beta-blockers in uncomplicated arterial hypertension: what is the evidence? Tijdschr Geneeskd. 2010; 66:213–221.

55. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005; 366:1545–1553.

56. De Caterina AR, Leone AM. The role of Beta-blockers as first-line therapy in hypertension. Curr Atheroscler Rep. 2011; 13:147–153.

57. Frohlich ED. Role of beta-adrenergic receptor blocking agents in hypertensive diseases: personal thoughts as the controversy persists. Ther Adv Cardiovasc Dis. 2009; 3:455–464.

58. Weir MR. Beta-blockers in the treatment of hypertension: are there clinically relevant differences? Postgrad Med. 2009; 121:90–98.

59. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol. 2010; 8:733–741.

60. Frishman WH, Saunders E. β-Adrenergic blockers. J Clin Hypertens (Greenwich). 2011; 13:649–653.

61. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005; 19:117–125.

62. Tonelli M, Lloyd A, Clement F, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ. 2011; 183:E1189–E1202.

63. Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006; 295:2046–2056.

64. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001; 103:276–283.

65. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97:1129–1135.

66. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998; 279:1643–1650.

67. Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 1999; 33:1294–1304.

68. Xu Z, Okamoto H, Akino M, Onozuka H, Matsui Y, Tsutsui H. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J Cardiovasc Pharmacol. 2008; 51:62–70.

69. Rutishauser J. Statins in clinical medicine. Swiss Med Wkly. 2011; 141:w13310.

70. Sposito AC, Santos SN, de Faria EC, et al. Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction. Arterioscler Thromb Vasc Biol. 2011; 31:1240–1246.

71. Morrissey RP, Diamond GA, Kaul S. Statins in acute coronary syndromes: do the guideline recommendations match the evidence? J Am Coll Cardiol. 2009; 54:1425–1433.

72. Kopecky SL. New statin intolerance clinic. Mayo Clin Cardiovasc Update . 2010; 8:6–7.

73. Zhou Z, Rahme E, Pilote L. Association between time of statin initiation after hospital discharge from acute myocardial infarction and risk of recurrence and mortality in patients > or =65 years of age. Am J Cardiol. 2006; 97:155–159.

74. Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA. 2002; 287:3087–3095.

75. Li YH, Wu HL, Yang YH, Tsai HS, Chao TH. Effect of early versus late inhospital initiation of statin therapy on the clinical outcomes of patients with acute coronary syndrome. Int Heart J. 2007; 48:677–688.

76. Dabhadkar KC, Kulshreshtha A, Ali MK, Narayan KM. Prospects for a cardiovascular disease prevention polypill. Annu Rev Public Health. 2011; 32:23–38.

77. Chaitman BR, Fisher LD, Bourassa MG, et al. Effect of coronary bypass surgery on survival patterns in subsets of patients with left main coronary artery disease. Report of the Collaborative Study in Coronary Artery Surgery (CASS). Am J Cardiol. 1981; 48:765–777.

78. Takaro T, Peduzzi P, Detre KM, et al. Survival in subgroups of patients with left main coronary artery disease. Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive Disease. Circulation. 1982; 66:14–22.

79. Hilliard AA, From AM, Lennon RJ, et al. Percutaneous revascularization for stable coronary artery disease temporal trends and impact of drug-eluting stents. JACC Cardiovasc Interv. 2010; 3:172–179.

80. Park SJ, Park DW. Left main stenting. Circ J. 2011; 75:749–755.

81. Riley RF, Don CW, Powell W, Maynard C, Dean LS. Trends in coronary revascularization in the United States from 2001 to 2009: recent declines in percutaneous coronary intervention volumes. Circ Cardiovasc Qual Outcomes. 2011; 4:193–197.

82. Al Suwaidi J, Berger PB, Holmes DR Jr. Coronary artery stents. JAMA. 2000; 284:1828–1836.

83. Saito S, Hosokawa G, Tanaka S, Nakamura S. PASTA Trial Investigators. Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. Catheter Cardiovasc Interv. 1999; 48:262–268.

84. Suryapranata H, Ottervanger JP, Nibbering E, et al. Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction. Heart. 2001; 85:667–671.

85. Li JJ, Ren Y, Chen KJ, et al. Impact of C-reactive protein on in-stent restenosis: a meta-analysis. Tex Heart Inst J. 2010; 37:49–57.

86. Sakhuja R, Mauri L. Controversies in the use of drug-eluting stents for acute myocardial infarction: a critical appraisal of the data. Annu Rev Med. 2010; 61:215–231.

87. Ejiri K, Ishihara M, Dai K, et al. Three-year follow-up of sirolimus-eluting stents vs. bare metal stents for acute myocardial infarction. Circ J. 2012; 76:65–70.

88. Widimsky P. Primary angioplasty vs. thrombolysis: the end of the controversy? Eur Heart J. 2010; 31:634–636.

89. Kadota K, Mitsudo K. Percutaneous coronary intervention with drug-eluting stent for unprotected left main trunk disease: safety and efficacy compared with bare metal stent. - Which coronary stent should be used for the left main trunk disease? BMS or DES? (DES side)-. Circ J. 2011; 75:1250–1254.

90. Kaneko H, Kijima M. Role of bare-metal stents for left main coronary artery disease in the era of drug-eluting stents. -Which coronary stent should be used for left main trunk disease? BMS or DES? (BMS-side)-. Circ J. 2011; 75:1243–1249.

91. Joviliano EE, Piccinato CE, Dellalibera-Joviliano R, Moriya T, Évora PR. Inflammatory markers and restenosis in peripheral percutaneous angioplasty with intravascular stenting: current concepts. Ann Vasc Surg. 2011; 25:846–855.

92. Räber L, Windecker S. Current status of drug-eluting stents. Cardiovasc Ther. 2011; 29:176–189.

93. Barbash IM, Waksman R. Current status, challenges and future directions of drug-eluting balloons. Future Cardiol. 2011; 7:765–774.

94. Dickersin K, Min YI. NIH clinical trials and publication bias. Online J Curr Clin Trials. 1993; Doc No 50.

95. Ioannidis J, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci U S A. 2001; 98:831–836.

96. Trikalinos TA, Churchill R, Ferri M, et al. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol. 2004; 57:1124–1130.

97. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ. 1997; 315:640–645.

98. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA. 1992; 267:374–378.

99. Decullier E, Chapuis F. Impact of funding on biomedical research: a retrospective cohort study. BMC Public Health. 2006; 6:165.

100. von Elm E, Röllin A, Blümle A, Huwiler K, Witschi M, Egger M. Publication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee. Swiss Med Wkly. 2008; 138:197–203.

101. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991; 337:867–872.

102. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998; 279:281–286.

103. Hutton JL, Williamson PR. Bias in meta-analysis due to outcome variable selection within studies. Appl Stat. 2000; 49:359–370.

104. Williamson PR, Gamble C, Altman DG, Hutton JL. Outcome selection bias in meta-analysis. Stat Methods Med Res. 2005; 14:515–524.

105. Kane RL, Wang J, Garrard J. Reporting in randomized clinical trials improved after adoption of the CONSORT statement. J Clin Epidemiol. 2007; 60:241–249.

106. Egger M, Smith GD, Altman DG. Systematic reviews in health care: meta-analysis in context. 2nd. London: BMJ Publishing Group;2001.